U.S. Markets open in 4 hrs 50 mins
  • S&P Futures

    3,974.50
    +8.75 (+0.22%)
     
  • Dow Futures

    33,830.00
    +27.00 (+0.08%)
     
  • Nasdaq Futures

    11,687.25
    +41.75 (+0.36%)
     
  • Russell 2000 Futures

    1,821.20
    +1.50 (+0.08%)
     
  • Crude Oil

    71.66
    +0.20 (+0.28%)
     
  • Gold

    1,803.60
    +2.10 (+0.12%)
     
  • Silver

    23.23
    -0.02 (-0.09%)
     
  • EUR/USD

    1.0552
    -0.0008 (-0.0739%)
     
  • 10-Yr Bond

    3.4910
    0.0000 (0.00%)
     
  • Vix

    22.60
    -0.08 (-0.35%)
     
  • GBP/USD

    1.2246
    +0.0008 (+0.0649%)
     
  • USD/JPY

    136.3240
    -0.3060 (-0.2240%)
     
  • BTC-USD

    17,218.48
    +389.88 (+2.32%)
     
  • CMC Crypto 200

    405.97
    +11.29 (+2.86%)
     
  • FTSE 100

    7,475.23
    +3.06 (+0.04%)
     
  • Nikkei 225

    27,901.01
    +326.58 (+1.18%)
     

Ice Bucket Challenge Beneficiary Throws Cold Water On Investors

Ice Bucket Challenge Beneficiary Throws Cold Water On Investors

Investors could see it coming from a mile away, but preparation doesn't quite relieve the sting of dilution. Fresh off the controversial approval for its Lou Gehrig's disease treatment, which was partially funded by the social media-driven Ice Bucket Challenge years ago, Amylyx Pharmaceuticals announced a public offering of common stock. The pricing wasn't set as of this writing, but the drug developer intends to offer up to 6.9 million shares of common stock.